Table 3_Drug-coated balloons vs. drug-eluting stents for coronary artery disease: an updat

23 randomized controlled trials comprising 8,123 patients compare drug-coated balloons (DCB) and drug-eluting stents (DES) for coronary artery disease. The dataset, uploaded by Yuting Wang in May 2026, contains pooled results for major adverse cardiac events, target lesion revascularization, and other clinical endpoints, with subgroup analyses by lesion type and drug coating.

Use Cases

• Compare treatment efficacy for in-stent restenosis vs. de novo lesions based on the subgroup analyses described.
• Assess safety signals for different drug coatings (paclitaxel vs. sirolimus) based on the cardiac death outcomes reported.
• Evaluate treatment outcomes by clinical presentation (STEMI, NSTEMI, unstable angina) based on the exploratory interaction analysis.
• Analyze angiographic and composite endpoint data for percutaneous coronary intervention strategies.

Strengths

• Includes data from 23 randomized controlled trials, a substantial evidence base.
• Provides specific odds ratios and confidence intervals for multiple clinical endpoints.
• Conducts detailed subgroup analyses by lesion type, vessel size, and drug coating.

Limitations

• Dataset scope is limited to a 20.0 KB document file; the underlying trial-level data is not included.
• Column-level documentation is absent; field semantics must be inferred from the article.
• The analysis includes exploratory subgroups with limited events, as noted in the description.

Provenance

Source

Systematic review and meta-analysis of trials from PubMed, Embase, CENTRAL, and Web of Science.

Collection Method

Pooled analysis of randomized controlled trials using random-effects models.

Time Range

Trials from database inception to March 2026.

Freshness

Last updated 2026-05-18 05:53:52